BCHE and Alzheimer disease: The two groups of currently approved anti-AD drugs—cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) [4,5,6] and N-methyl-d-aspartate receptor (NMDAR) antagonists (memantine) [7,8]—can, at best, only attenuate AD symptoms for a limited period of time.